Methods of using a complex (scuPA/suPAR) which has thrombolytic activity
under physiological conditions and in the presence of IgG, or of at least one IgG-derived
peptide, which complex comprises a single chain urokinase type plasminogen activator
(scuPA) and a soluble urokinase plasminogen activator receptor (suPAR), for the
treatment and/or prevention of thromboembolic disorders associated with the formation
of fibrin clots are disclosed.
